Background: Colorectal cancer (CRC) is one of the most common malignant tumors in the world. Siah E3 ubiquitin protein ligase 1 (Siah1) has been identified as a tumor suppressor gene and plays an important role in the development of malignant tumors. However, the potential role and molecular mechanism of Siah1 in the development and progression of CRC is still unclear.
adenomatous polyposis coli (APC) [2] , tumor protein p53 (TP53) and so on [3, 4] . Although many diagnostic and therapeutic strategies have advanced, the clinical outcome and prognosis of CRC remains unsatisfactory. Therefore, it is necessary to explore more potential biomarkers involved in the initiation and development of CRC in order to predict the prognosis for this disease.
Ubiquitination plays an important role in the development of colorectal cancer. It regulates cellular biological processes through the ubiquitin critical proteins. Siah E3 ubiquitin protein ligase 1, also known as Siah1, is a human homolog of Drosophila seven in absentia (sina) gene. The Siah1 protein is a member of the E3 ubiquitin ligase family, which are highly conserved in evolution. E3 ubiquitin ligase enzymes can promote the ubiquitination process by enhancing the ubiquitination of target proteins. Siah1 can bind to a variety of target proteins, thereby triggering their ubiquitylation and degradation by the ubiquitin-proteasome pathway. These target proteins include NcoR (nuclear receptor co-repressor), TRAF (TNF receptor associated factor), β-catenin, c-Myb (c-MYB proto-oncogene), APC, Kid and so on [5] [6] [7] [8] .
Previous studies have shown that Siah1 is a target of MiRNAs [9] [10] [11] and other proteins [12] that are likely to affect the occurrence and progress of tumor [13] . Recent studies [14] [15] [16] [17] [18] have found that Siah1 plays an important role in promoting apoptosis under hypoxic conditions or by the P53-induced pathway, and during the process of tumor development, Siah1 behaves as a tumor suppressor. It has been reported that Siah1 is downregulated or even deficient in different tumors [19] [20] [21] . More importantly, Siah1 mediates the ubiquitination of target proteins that regulate general functions necessary for tumorigenesis and the progression of cancer, such as cell growth arrest, apoptosis, and DNA repair, etc. [22] [23] [24] [25] . These findings indicate that Siah1 plays an important role in the development of malignant tumors. However, the potential role and molecular mechanism of Siah1 in the development and progression of CRC is still unclear.
Uncontrolled, unlimited and accelerated multiplication is one of the most fundamental biologic behaviors of cancer cells. Many pathways are involved in the proliferation and apoptosis of malignant cells, such as P53 [26] , AKT [27, 28] and Hippo signaling pathways, which are also implicated in the control of cell proliferation and death [29] . The ubiquitination of some key proteins leads to abnormal regulation of these signaling pathways. However, the ubiquitination substrates of Siah1 in the progression of CRC remain unclear.
In this study, we aimed to detect the expression of Siah1 was in CRC tissues, analyze the relationship between Siah1 expression and clinicopathological parameters, and explore the biological function and molecular mechanism of Siah1 in the tumorigenesis and development of CRC.
Methods

Patients and specimens
This study analyzed 170 formalin-fixed paraffin-embedded human colorectal carcinoma samples, which were histopathologically and clinically diagnosed at Nanfang Hospital, Southern Medical University between 2010 and 2015. Prior approval was obtained from the Institutional Research Ethics Committee. Clinical information of the samples is summarized in Additional file 1: Table S1 . The 50 freshly collected colorectal cancer tissues and paired normal mucosal tissues were frozen and stored in liquid nitrogen until use.
Immunohistochemistry
Immunohistochemistry (IHC) staining and scoring were done as previously described [30, 31] 
Cell cultures
The human CRC cell lines (SW480, HCT116) were originally purchased from the American Type Culture Collection (Manassas, VA, USA). They were cultured in RPMI-1640 medium (Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS; PAA Laboratories, Pasching, Austria) at 37 °C with 5% CO 2 .
Vector construction and retroviral infection
The Siah1 construct was generated by subcloning PCR amplified full-length human Siah1 cDNA into pEZLv105. For silencing of Siah1, 2 short hairpin RNA (shRNA) sequences were cloned into the GV248 vector to generate GV248-RNAi(s). Sequences of shRNA primers are provided in Additional file 1: Table S3 . Retroviral production and infection were performed as previously described [32] . Stable cell lines expressing Siah1 or Siah1-shRNA were selected for 10 days with 1.0 mg/mL puromycin.
RT-QPCR and Western blot analyses
RT-QPCR(Realtime-Quantitative reverse transcription polymerase chain reaction) and Western blot were done as previously described [33] . RT-QPCR primers were designed using Primer 5.0 software. Sequences of the primers are provided in Additional fie 1: Table S3 .
Western blot was performed according to standard methods as described previously [34] . Anti-Siah1 
Tumorigenesis in nude mice
Xenograft tumors were generated by subcutaneous injection of cells (2 × 10 6 for SW480/Lv105 and SW480/Siah1) on the hind limbs of 4-6 weeks old Balb/C athymic nude mice (nu/nu; the Animal Center of Southern Medical University, Guangzhou, China n = 6 for each group). Subsequent treatment of all mice was performed as previously described [35] . We counted five randomly selected high-power fields and calculated the average percentage of stained cells among the total cell as the Ki-67 (Bioworld, #bs1454, dilutions: 1:200) index in subsequent IHC staining [36] . The data were calculated using paired t test.
Statistical analysis
All statistical analyses were performed using SPSS version 20.0. Mann-Whitney U and Chi square tests were used to analyze the relationship between Siah1 expression and the clinicopathologic features of CRC. Survival curves were plotted by using the Kaplan-Meier method and compared using the log-rank test. Univariate survival distribution was compared by the log-rank test. Functional experiments (MTT and wound-healing assays) were analyzed via one way ANOVA. P < 0.05 was considered significant.
Accession numbers for the data sets
The GEO database (GSE38832) was used to analyze the relationship between the expression of Siah1 and the 5-year overall survival of the CRC patients.
Biological information analysis
A computational gene co-expression search engine was used to analyze the relationship between the co-expression of Siah1 and the related signaling pathways. SearchBased Exploration of Expression Compendium (SEEK) (http://seek.princ eton.edu), which provides biologists with a way to navigate the massive human expression compendium that now contains thousands of expression datasets, to analyze co-expression of Siah1 in CRC data provided by the search engine, then KEGG analysis (DAVID Bioinformatics Resources 6.8, http://david .abcc. ncifc rf.gov/) was performed using the top 500 most negative-correlated genes.
Results
Siah1 is downregulated in CRC tissues, and its expression was associated is progression and poor prognosis in CRC
Western blot was used to detect the expression of Siah1 in 10 CRC tissues. The result showed that Siah1 was significantly downregulated in CRC tissues (T) compared with their paired adjacent noncancerous tissues (N) (Fig. 1a) . The result from RT-PCR revealed that the Siah1 mRNA level was also downregulated in CRC tissues ( Table S1 ). The Mann-Whitney U test was used to analyze the relationship between Siah1 expression and clinicopathologic features of CRC. As showed in Additional file 1: Table S1 , Siah1 expression was strongly correlated with T classification (P = 0.005), N classification (P = 0.003), and M classification (P = 0.030). We further confirmed these data by Spearman correlation analysis (Additional file 1: Table S2 ), and the coefficients of correlation between Siah1 expression and T classification, N classification, M classification were − 0.218 (P = 0.004), − 0.196 (P = 0.013), − 0.230 (P = 0.003) and − 0.166 (P = 0.030), respectively. Kaplan-Meier survival analyses of five published CRC data sets (GSE38832) [37] suggested that patients with high Siah1 levels had significantly better overall survival (P < 0.001) and disease-free survival (P = 0.001, Fig. 1d ) than patients with low Siah1 levels. These results indicated that Siah1 expression was closely associated with the progression and prognosis of CRC.
Exogenous overexpression of Siah1 inhibits the proliferation and migration of human CRC cells
To evaluate whether Siah1 plays a role in the proliferation of human CRC cells, medium expression cell lines HCT116/SW480 were selected to follow up subsequent functional study (Additional file 4: Figure S2C ), stable Siah1 expressing CRC cell lines SW480/Siah1 and HCT116/Siah1 were established (Fig. 2a) . The results of MTT assays revealed that, compared to the control group, Siah1 overexpression decreased the growth rate of SW480/Siah1 and HCT116/Siah1 ( Fig. 2b ; SW480/Siah1: Green, patients with low Siah1 expression (n = 115); blue, patients with high expression of Siah1 (n = 55). GSE38832 showed the effect of Siah1 expression level on overall survival of CRC patients(lower) P < 0.001; HCT116/Siah1: P < 0.001). As demonstrated in colony formation assays, SW480/Siah1 and HCT116/ Siah1 cells formed fewer colonies compared with the control groups ( Fig. 2c ; SW480/Siah1: P < 0.05; HCT116/ Siah1: P < 0.001). We next investigated the effect of Siah1 on the tumorigenesis of CRC cells by soft-agar assay. The results indicated that Siah1 overexpression significantly inhibited the growth of SW480 and HCT116 cells, as displayed by the reduction in colony number and size on soft agar (Fig. 2d , SW480/Siah1: P < 0.0001; HCT116/ Siah1: P < 0.0001). To confirm this effect in vivo, we conducted tumorigenesis assays in nude mice by subcutaneous injection of SW480/Lv105 and SW480/Siah1 cells. Compared to control cells, SW480/Siah1 cells showed (Fig. 2e) (n = 6, P < 0.05). In addition, we also found that the tumors formed by SW480/Siah1 cells exhibited much lower proliferation indexes (the positive rate of Ki-67) than the tumors formed by SW480/Lv105 cells (Fig. 2f ) . We also verified the same results with HCT116 cell lines ( Figure S2A and S2B) (n = 6, P < 0.05). The results of wound-healing assays and transwell chamber invasion assays showed that overexpression of Siah1 in SW480 and HCT116 inhibited the migratory speed and number of CRC cells (Fig. 3a, b ; transwell: SW480/Siah1: P < 0.0001; HCT116/Siah1: P < 0.05), compared with control cells.
Exogenous knockout of Siah1 promotes the proliferation and migration of human CRC cells
To further confirm the role of Siah1 in the proliferation of CRC cells, we knocked down endogenous Siah1 expression in SW480 and HCT116 CRC cells by using specific short hairpin RNAs (Additional file 4: Figure  S2 and Additional file 5: Figure S3 ; Fig. 4a ). MTT assays and colony formation assays (Fig. 4b, c; MTT: SW480-GV248/SW480-Siah1-shRNA: P < 0.001; HCT116-GV248/HCT116-Siah1-shRNA: P < 0.001; colony formation assays: SW480-GV248/SW480-Siah1-shRNA: P < 0.0001; HCT116-GV248/HCT116-Siah1-shRNA: P < 0.005) demonstrated that silencing of Siah1 expression caused evidently more rapid growth in SW480 and HCT116 cells, compared with the control cells. Moreover, knockdown of endogenous Siah1 in SW480 and HCT116 cells caused a striking increase in colony number and an obvious growth of colony size on soft agar ( Fig. 4d ; SW480-GV248/SW480-Siah1-shRNA: P < 0.0001; HCT116-GV248/HCT116-Siah1-shRNA: P < 0.0001). Moreover, we also conducted tumorigenesis assays in nude mice by subcutaneous injection of SW480/ GV248 (negative control) and SW480/Siah1-shRNA (exogenous knockout) cells. In contrast to control cells, SW480/Siah1-shRNA cells showed faster tumor growth and remarkably bigger tumor volume (Fig. 4e) (n = 6, P < 0.05). In addition, we also found that the tumors formed by SW480/Siah1 cells exhibited much higher proliferation indexes (the positive rate of Ki-67) than the tumors formed by SW480/GV248 (Fig. 4f ) . We also verified the same results with HCT116 cell lines (Additional file 5: Figure S3C and D) (n = 6, P < 0.05). In addition, the results of wound-healing assays and transwell chamber invasion assays also demonstrated that endogenous knockout of Siah1 enhanced migratory ability of SW480 and HCT116 cells, as indicated by an increase in migratory speed and number of CRC cells (Fig. 5a, b ; transwell: SW480-GV248/SW480-Siah1-shRNA: P < 0.001; HCT116-GV248/HCT116-Siah1-shRNA: P < 0.0001).
Siah1 regulated the activity of the MAPK, PI3K-AKT and Hippo pathways through the ubiquitination of AKT and YAP in CRC cells
We analyzed the negative co-expression of Siah1 in CRC, and KEGG (Kyoto Encyclopedia of Genes and Genomes) signaling pathway analysis was conducted (http://seek. princ eton.edu/). The results of biological information revealed that MAPK, Hippo, Wnt, and VEGF (Vascular Endothelial Growth Factor A) signaling pathways were significantly enriched (Fig. 6a) . We further detected the expression of genes associated with these pathways through Western blot. Siah1 remarkably decreased the levels of ERK (Extracellular regulated protein kinases), phosphorylated ERK (p-ERK), AKT, phosphorylated AKT (p-AKT), JNK (c-Jun N-terminal kinase), phosphorylated JNK (p-JNK) and Yap (Fig. 6b) , whereas silencing of endogenous Siah1 dramatically increased expression levels of ERK, phosphorylated ERK (p-ERK), AKT, phosphorylated AKT (p-AKT), JNK, phosphorylated JNK (p-JNK) and Yap (Fig. 6c) . These results indicated that Siah1 inhibits proliferation through regulating the activity of the MAPK and Hippo signaling pathways (Additional file 5: Figure S3E and F).
Siah1 acts as a member of the E3 ubiquitin ligase family, which is involved in the ubiquitylation and degradation of some specific proteins. We next detected the interaction between Siah1 and AKT or YAP by Co-Immunoprecipitation (Co-IP) in SW480. As Fig. 6d shows, Siah1 interacted with AKT and YAP. Furthermore, ubiquitylation detection assay was used to examine poly-ubiquitylation levels of AKT and YAP. The results demonstrated the K48-polyubiquitination levels of AKT and YAP were higher in Siah1-transfected cells than in control cells (Fig. 6e) . However, there was no significant difference in K63-polyubiquitination levels of AKT and YAP (Additional file 4: Figure S2D , E), suggesting that Siah1 promotes AKT and YAP K48-polyubiquitination levels and ubiquitin proteasome degradation. Taken together, these data indicated that Siah1 represses the occurrence and development of CRC by promoting the ubiquitylation of AKT and inhibiting the activity of the MAPK, PI3K-AKT and Hippo pathways.
Discussion
The tumorigenesis and progression of CRC is a complex process with multiple steps, factors and stages, accompanied by the activation of oncogenes and the inactivation of tumor suppressor genes. Chromosome 16q12-q13 is a region that is frequently deleted in a large variety of human tumors, such as prostate adenocarcinomas [38] , primary breast cancers [39] , hepatocellular carcinoma [40] , ovarian cancers [41] , Wilms' tumors [42] and colorectal carcinomas [43] . The Siah1 gene is located at 16q12.1, and it is reported that the expression of Siah1 is often reduced or absent in various types of human cancers, including bladder cancer, lung cancer, breast cancer and hepatocellular carcinomas [17, 20, 44] . In this study, we found that Siah1 was downregulated in CRC, and low expression of the Siah1 protein was dramatically correlated to aggressive TNM staging and poor prognosis in CRC patients. Each bar represents the mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001. Scale bar: 50 μm The Siah1 protein belongs to the highly conserved family of E3 ubiquitin ligases. Structurally, the Siah1 protein contains two zinc finger cytokine-rich domains and shares 77% identity with Siah-2 [14] , but they have different substrate targets [13] . A large number of studies have shown that Siah1 plays a role as a tumor suppressor gene in the process of tumorigenesis and evolution. It has been documented that the overexpression of Siah1 in breast cancer cells and hepatocellular carcinoma cells induces apoptosis of cancer cells and inhibits the progression of cancer [20, 45] . Our previous studies showed that miR-450-5p targeted the 3′-UTR (3′-Untranslated Region) of Siah1 to regulate the progression of colorectal cancer [10] . In the present study, we confirmed that exogenous overexpression of Siah1 suppressed CRC cells proliferation, invasion and tumor growth both in vitro and in vivo. Furthermore, this may also influence tumor cells' interactions with drugs through forming complexes with NMNT (Nicotinamide N-methyltransferase) [46] . Exogenous knockout of Siah1 produced the opposite results. These findings indicate that Siah1 may serve as a tumor suppressor role in CRC and may be a novel potential prognostic factor of CRC.
Although Siah1 has been identified to regulate proliferation, invasion and tumor growth in CRC, the possible molecular mechanism remains largely unknown. As the results of biological information, we have confirmed that the MAPK, and Hippo pathways were significantly enriched in CRC with lower Siah1 expression. We also found that the P53_PATHWAY was significantly enriched upon Siah1 overexpression (Additional file 4: Figure S2B ). It has been reported that the PI3K/AKT pathway was related to P53 pathway [47] . As the literature report, the Hippo signaling pathway can interact with the signaling pathways of NF-κB, MAPK and other signals during bonebreaking cell formation. Especially in the Hippo-and-MAPK signaling pathway, YAP/TAZ/TEAD can activate ERK, JNK, etc. to inhibit apoptosis [48] . So, we attempted to detected the key protein of these pathways. We demonstrated that Siah1 can regulate the activity of AKT, MAPK and Hippo signaling pathways in CRC cells.
More importantly, it has been documented that Siah1 facilitates ubiquitination and proteasome-dependent degradation of diverse substrate proteins with multiple functions. E3 ubiquitin ligase enzymes play a key role in target protein identification and the active regulation of the ubiquitination system. K48 and K63 ployUb chains have been widely studied. The polyUb chain modified protein with Lys 48 was degraded by the ubiquitin-proteasome pathway of the 26S proteasome; polyUb K63 is Fig. 7 Model: Siah1, downstream of miR450b-5p, promoting AKT and YAP ubiquitylation and proteasome degradation to regulate the activity of the PI3K-AKT and Hippo signaling pathways, ultimately leading to an aggressive CRC phenotype involved in the internalization and lysosomal degradation of membrane surface receptors [49, 50] .
As the key molecule of PI3K-AKT signaling, AKT plays an oncogenic role in the development and progression of cancers, and it could also be a potential target for tumor therapy [51] . For example, TRAF6 catalyzed K63 poly-ubiquitylation level of AKT, contributing to the enhancement of AKT membrane localization and phosphorylation, thus promoting oncogenic AKT activation [52] . Another report showed that, activated AKT is a poly-ubiquitination target of MULAN (mitochondrial ubiquitin ligase activator of NF-κB) and promotes p-AKT degradation [53] . We found was that Siah1 could interact with AKT and undergo PloyUb K48 chain ubiquitination in CRC cells. Related research shows that YAP, as one of the core molecules in Hippo signaling, was regulated by E3 ubiquitin ligases [54] [55] [56] . That is, it has been documented that CK1δ/ε recruits the SCF (β-Trcp1) E3 ubiquitin ligase, which facilitates YAP ubiquitylation, ultimately leading to YAP degradation [55] . Our research also shows that Siah1 promotes YAP degradation in PolyUb K48 chains instead of K63. The results from our research demonstrated that Siah1 interacts with AKT and YAP, and it catalyzes the K48 poly-ubiquitylation and proteasome degradation of AKT and YAP in colorectal cancer cells.
Conclusion
Our study suggested that Siah1 is downregulated in CRC and might be a valuable prognostic marker of CRC progression. Dysregulation of Siah1 plays a vital role in promoting the development and progression of CRC, partially through promoting AKT and YAP ubiquitylation and proteasome degradation to regulate the activity of the PI3K-AKT and Hippo signaling pathways (Fig. 7) . However, the mechanism of MAPK regulation by Siah1 requires further investigation.
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